Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key "don't eat me signals" found in cancer cells heightens the immune response and ...

Colorectal cancer (CRC) remains one of the most prevalent malignancies and a leading cause of cancer-related mortality worldwide. Beyond tumor-intrinsic ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Engineered oncolytic bacteria have emerged as a promising therapeutic platform for precision cancer treatment, offering tumor-specific colonization, immune activation, and controllable therapeutic ...

Cancer models retaining original tumor characteristics can be developed through 3D bioprinting, allowing for rapid evaluation of drug responses. A team of researchers led by Jinah Jang from Pohang ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...